Under 10% of patients eligible to benefit from GLP-1 drugs like Wegovy are able to get them, states the global health agency as it issues its inaugural recommendations on the medications.
Given more than one billion people worldwide now living with obesity, it is advocating for more widespread and fairer access to these injectable treatments.
According to projections, more than two billion are projected to be obese by 2030 unless action is taken.
"The new guidance recognises that obesity is a lifelong illness that can be treated with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are significant hurdles to widespread access to the jabs that can assist patients in reducing substantial weight, says the body.
Skinny Jab Scarcity
Despite the current most optimistic scenario, the supply of these medications might only reach about 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline encourages governments and firms to expand access, through approaches like patent sharing.
A patent on semaglutide – the main ingredient of a leading brand – is due to expire in a number of countries in 2026.
How Weight-Loss Drugs Operate
GLP-1 drugs replicate a natural hormone to reduce digestion speed, curb appetite and enhance satiety so users eat less.
Patients typically begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Studies indicates users may regain a significant portion after a year of discontinuing the drug, as their usual hunger return.
Being above a healthy weight elevates your likelihood for developing diseases, including type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity affects people in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.